Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK), Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN), Bristol Myers Squibb Co. (BMY): A New Diabetes Duo Emerges

Even when you’re a behemoth, you’ve got to know your strengths.

That’s the message from today’s announcement that Pfizer Inc. (NYSE:PFE) is out-licensing its diabetes drug candidate ertugliflozin to Merck & Co., Inc. (NYSE:MRK). The pharma giant is usually the one bringing in products rather than sending them elsewhere.

Pfizer Inc. (NYSE:PFE)

But Pfizer Inc. (NYSE:PFE) isn’t exactly known for diabetes. It could certainly make the push, but having a partner that’s experienced in the space should produce higher sales with lower expenses, hopefully making up for whatever it has to give up.

And what a good partner Pfizer Inc. (NYSE:PFE) picked. Merck & Co., Inc. (NYSE:MRK) has lots of experience in the space selling Januvia. Sales of the Januvia-containing drugs — it comes alone or in combination with other diabetes drugs — were up 23% last year to $5.7 billion .

As part of the deal, Merck & Co., Inc. (NYSE:MRK) paid Pfizer Inc. (NYSE:PFE) $60 million now and is on the hook for other unspecified clinical, regulatory, and commercial milestones. Merck & Co., Inc. (NYSE:MRK) Pfizer will split the revenue and cost on a 60/40 basis.

In addition to developing ertugliflozin, which is ready to enter phase 3 trials later this year, the duo plans to develop pills combining ertugliflozin with metformin and Januvia.

The ertugliflozin-Januvia combination could be a big blow to Johnson & Johnson (NYSE:JNJ)‘s recently approved Invokana. The drug is an SGLT-2 inhibitor, the same class as ertugliflozin. Invokana will have a couple of years’ head start, but it’ll have a hard time competing against a ertugliflozin-Januvia combination pill for patients that need to take both drugs. Doctors and patients both prefer fewer pills, so assuming that the efficacy and safety are similar, the combination product should win out.

AstraZeneca plc (ADR) (NYSE:AZN) and
Bristol Myers Squibb Co. (NYSE:BMY) Squibb are also developing an SGLT-2 inhibitor called Forxiga, but the Food and Drug Administration issued a complete response letter for the drug, requesting more data. If the duo can ever get Forxiga approved in the U.S., it won’t have an issue competing with an ertugliflozin-Januvia combination because AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) have a drug, Onglyza, that’s in the same class as Januvia. They can develop a combination product internally.

Forxiga’s rejection in the U.S. highlights another reason why this is a good move for Pfizer: Sharing the cost of the phase 3 program, which will likely entail many clinical trials, reduces the company’s risk should something go wrong.

The article A New Diabetes Duo Emerges originally appeared on Fool.com is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...